Zealand Pharma and Novo Nordisk Ink Licensing and Development Deal
Zealand Pharma and Novo Nordisk have signed a global licensing and development deal focused on Zealand’s hypoglycemia drug Zegalogue (dasiglucagon).
Zegalogue was approved by the FDA in March 2021 as an injectable treatment for severe hypoglycemia in adult and pediatric patients age six years and older with diabetes.
Zealand will get an upfront payment of about $3 million and is eligible to receive more than $6 million in near-term development, regulatory and manufacturing-based milestones, said the company in a statement. Zealand is also eligible to land more than $29 million in sales-based milestones and tiered royalties.
Under the terms of the deal, Zealand will retain all nonlicensed intellectual property rights to its other dasiglucagon development programs.